We would test the possible use of venetoclax in the pediatric AML setting and evaluated the BCL-2 levels in a cohort of pediatric AML samples, finding the majority of KMT2A-rearranged AML patients to be allocated in Q3 + Q4 quartiles and to have significantly high levels of BCL-2, phospho-BCL-2 S70, and MCL-1, suggesting that this antiapoptotic signaling is particularly upregulated in this subgroup. This evidence concerns the gene MCL1 and acute myeloid leukemia.